Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 15/20 | 0.49 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.49 |
| ▸ | ATXN2 | Q99700 | 13/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17311089 | 1.00 | ENPP2 (0.49) | ENPP2DGAT2ATXN2GRM5HTR2A | |
| SCHEMBL17311088 | 1.00 | ENPP2 (0.49) | ENPP2DGAT2ATXN2GRM5HTR2A | |
| SCHEMBL21313848 | 0.90 | ENPP2 (0.52) | ENPP2DGAT2ATXN2 | |
| SCHEMBL17310750 | 0.90 | ENPP2 (0.52) | ENPP2DGAT2ATXN2 | |
| SCHEMBL17310752 | 0.90 | ENPP2 (0.52) | ENPP2DGAT2ATXN2 | |
| SCHEMBL16963218 | 0.89 | ENPP2 (0.54) | ENPP2DGAT2ATXN2 | |
| SCHEMBL16962454 | 0.86 | ENPP2 (0.53) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL21313892 | 0.84 | ENPP2 (0.63) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL16962631 | 0.84 | ENPP2 (0.63) | ENPP2DGAT2ATXN2HTR2AABAT | |
| SCHEMBL16962872 | 0.82 | ENPP2 (0.53) | ENPP2DGAT2ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | claimed |